Global Brain Monitoring Market 2024-2031

Global Brain Monitoring Market 2024-2031

Brain Monitoring Market Size, Share & Trends Analysis Report by Type (MRI Scanners, CT Scanners, EEG Devices, PET Scanners, Sleep Monitoring Devices, Cerebral Oximeters, EMG Devices, ICP Monitors, MEG Devices, and TCD Devices), by Application (Parkinson's Disease, Traumatic Brain Injury, Epilepsy, Dementia, Sleep Disorders, Stroke, Headache Disorders, and Others), and by End User (Hospitals, Diagnostic Centers, and Ambulatory Surgery Centers (ASCs) & Clinics), Forecast Period (2024-2031)

Brain monitoring market is anticipated to grow at a CAGR of 7.8% during the forecast period (2024-2031). The brain monitoring market is experiencing significant growth, driven by factors such as the rising prevalence of neurological disorders, advancements in brain imaging technologies, and an aging population. Additionally, increasing awareness and screening programs, along with the preference for non-invasive diagnostic techniques, contribute to the market's expansion. The integration of AI and machine learning algorithms in brain monitoring systems improves diagnostic accuracy and enables real-time decision-making. This market plays an essential role in modern healthcare delivery and neurological research, supporting early diagnosis, personalized treatment planning, and disease progression monitoring. Technological innovations focus on enhancing user experience, and data accuracy, and expanding the capabilities of brain monitoring systems, further contributing to the market's significance.

Market Dynamics

Increasing Stroke Incidence and Mortality

The rising incidence of strokes in countries with low and middle incomes indicates the significance of effective stroke preventative measures methods, demanding the utilization of brain monitoring technology for rapid detection and rehabilitation. According to the World Stroke Organization new (WSO) Lancet Neurology Commission report, governments and healthcare systems are being urged to implement stroke prevention recommendations. The report projects a significant increase in stroke cases, estimating that by 2050, strokes will claim 9.7 million lives annually, with over 90.0% of these deaths occurring in low- and middle-income countries. The rise in stroke incidence among young and middle-aged individuals, driven by factors such as hypertension and diabetes, is contributing to a global cost projection of $2.3 trillion by 2050. Additionally, the prevalence of stroke-related disability is increasing at a faster rate in LMICs compared to high-income countries.

Technological Advancements in Diagnosis and Treatment

Technological advancements in diagnostic imaging and monitoring have significantly improved the detection and treatment of breast cancer and neurological disorders. About 10.0% to 15.0% of individuals with stage IV breast cancer have brain metastases. The risk of brain metastasis is usually highest for individuals with more aggressive subtypes of breast cancer, such as HER2-positive or triple-negative breast cancer. According to the National Breast Cancer Foundation, Inc., in April 2024, breast cancer has a considerable influence on women in the US, with an estimated 310,720 new cases of invasive breast cancer and 56,500 new cases of non-invasive breast cancer expected in 2024. However, it is important to note that there are currently over 4 million breast cancer survivors in the US, highlighting the progress in treatment and care. Tragically, breast cancer remains a leading cause of death among women, with an estimated 42,250 US women expected to lose their lives to the disease in 2024. The risk of recurrence varies depending on the type and stage of the initial breast cancer, with the highest risk typically occurring in the first few years after treatment and decreasing over time.

Market Segmentation

Based on the type, the market is segmented into magnetic resonance imaging (MRI) scanners, computerized tomography (CT) scanners, electroencephalograph (EEG) devices, positron emission tomography (PET) scanners, sleep monitoring devices, cerebral oximeters, electromyography (EMG) devices, intracranial pressure (ICP) monitors, magnetoencephalography (MEG) devices, and transcranial doppler (TCD) devices.

Based on application, the market is segmented into Parkinson's disease, traumatic brain injury, epilepsy, dementia, sleep disorders, stroke, headache disorders, and others (Huntington's disease).

Based on end-user, the market is segmented into hospitals, diagnostic centers, and ambulatory surgery centers (ASCs) & clinics.

Electroencephalograph is Projected to Emerge as the Largest Segment

The primary factor supporting the segment's growth includes the growing rate of cardiovascular diseases and comorbid conditions, strokes, and other neurological associated with cardiovascular diseases that usually require extensive brain monitoring. To examine brain activity and forecasting in specialized patients with cardiovascular comorbidities, electroencephalogram (EEG) devices are essential. According to the World Heart Federation, in 2023, cardiovascular diseases affect over half a billion individuals globally, causing 20.5 million deaths in 2021. While advances in cardiovascular medicine can prevent up to 80.0% of premature heart attacks and strokes, they often don't benefit communities most in need, with 4 in 5 CVD deaths in low- and middle-income countries and progress concentrated in high-income countries.

Epilepsy Sub-segment to Hold a Considerable Market Share

The rising prevalence of neurological disorders globally has developed a need for the advancement of brain monitoring technologies, which can aid in precise diagnosis, continuous monitoring of seizure activity, and enhanced treatment efficacy. According to the World Health Organization (WHO), in February 2024, epilepsy, a neurological disease affecting 50 million individuals globally, can lead to 70.0% seizure-free life, but premature death risk is three times higher, especially in low-income countries.

Regional Outlook

The brain monitoring market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Healthcare Infrastructure in Rural Areas in the Asia-Pacific Region

Increasing the value of healthcare infrastructure in rural regions through community-based screening programs, telemedicine platforms, and mobile health initiatives can help dementia patients acquire immediate care and increase the rate of early detection. According to the National Center for Biotechnology Information, in July 2023, dementia prevalence in India was 7.4%, with 8.8 million adults over 60 living with it, notably higher among females and in rural areas.

North America Holds Major Market Share

The increasing prevalence of brain injuries renders modern monitoring technologies, such as electroencephalogram (EEG), magnetic resonance imaging (MRI), and computed tomography (CT) scans, essential for efficient diagnosis and treatment. According to the American Society for Biochemistry and Molecular Biology, in March 2021, brain injuries in the US occur every nine seconds, resulting in over 3.5 million injuries annually. These injuries can be non-traumatic or traumatic, depending on the source. In the US, 2.8 million individuals sustain a TBI annually, with 280,000 hospitalizations. About 50,000 are fatal, with 155 deaths daily from TBI-related injuries. One in every 60 people has a TBI-related disability.

The major companies serving the brain monitoring market are GE HealthCare Technologies Inc., Integra LifeSciences Corp., Medtronic PLC, Koninklijke Philips N.V., and Masimo Corp., among others. The market players are increasingly focusing on business expansion and development by applying strategies such as collaborations, mergers and acquisitions to stay competitive in the market.

Recent Developments

In January 2024, Aditxt acquired a portfolio of EEG brain monitoring technologies and devices, formerly owned by Brain Scientific. The acquisition enabled Pearsanta to enter the neurology monitoring market, offering enhanced diagnostics and monitoring for accurate diagnoses and treatment decisions.

In July 2023, Beacon Biosignals acquired Dreem's research and development business, enabling clinical trial assessments at scale by integrating Dreem's hardware with Beacon's next-generation EEG analytics platform.